Levetiracetam use in critically ill patients

Neurocritical Care

Volumn 7, Issue 2, 2007, Pages 140-147

  Szaflarski, Jerzy P ^a   Meckler, Jason M ^a   Szaflarski, Magdalena ^a   Shutter, Lori A ^a   Privitera, Michael D ^a   Yates, Stephen L ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

Epilepsy; Hemorrhage Tumor; ICU; Levetiracetam (LEV); Outcome; Stroke

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; PHENYTOIN;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; BLEEDING; BRAIN DISEASE; BRAIN TUMOR; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RASH; SEIZURE; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BRAIN DISEASES; BRAIN NEOPLASMS; CEREBRAL HEMORRHAGE; COMORBIDITY; CRITICAL ILLNESS; EPILEPSY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MIDDLE AGED; PIRACETAM; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 36949021797     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-007-0042-8     Document Type: Article

References (37)

1. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA 2004;291(5):615-20.
2. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291(5):605-14.
3. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41(9):1179-86.
4. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55(2):236-42.
5. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9(2):80-7.
6. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41(10):1276-83.
7. van Breemen MS, Vecht CJ. Optimal seizure management in brain tumor patients. Curr Neurol Neurosci Rep 2005;5(3):207-13.
8. Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol 2005;54(1):34-8.
9. Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN. The use of levetiracetam in refractory status epilepticus. Seizure 2006;15(3):137-141.
10. Wagner GL, Wilms EB, Van Donselaar CA, Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 2003;12(8):585-6.
11. Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998;284(2):474-9.
12. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001;10(4):287-93.
13. Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991;265(10):1271-7.
14. Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36(3):583-7.
15. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85(2):77-85.
16. Truog RD, Brock DW, Cook DJ, et al. Rationing in the intensive care unit. Crit Care Med 2006;34(4):958-63; quiz 71.
17. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003;4(6):702-9.
18. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68(6):402-8.
19. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64(11):1868-73.
20. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107(3):165-75.
21. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27(3):195-204.
22. Christe W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997;26(3):451-60.
23. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3(1):70-6.
24. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27(3):205-13.
25. Leppik IE. Epilepsy in the elderly. Rev Neurol Dis 2004;1(Suppl 1):S44-55.
26. Ficker D, Meckler J, Szaflarski J, Shutter L, Warnick R. Use of Levetiracetam as pre-operative prophylaxis in brain tumour surgery patients. In: 26th International Epilepsy Congress; 2005; Paris, France: Epilepsia; 2005. p. Suppl.6:106.
27. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286(5439):487-91.
28. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338(8):499-505.
29. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356(9226):285-90.
30. Khan RB, Hunt DL, Thompson SJ. Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004;19(2):97-101.
31. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340(8):618-26.
32. Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health 2003;93(12):2067-73.
33. Specchio LM, Boero G, Specchio N, et al. Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. Seizure 2006;15(2):112-6.
34. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005;46(2):324-6.
35. Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003;4(5):537-47.
36. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003;61(9):1218-21.
37. Cramer JA, De Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4(2):124-32.